This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASH 2023
Presentations
Session Info Card
Seagen Development Pipeline
SGN-35C | Lymphomas | Abstract #1440
SGN-35C: a novel CD30-directed antibody-drug conjugate for the treatment of lymphomas
Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #611
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early-stage classical Hodgkin lymphoma: Updated results reporting progression-free survival in an ongoing phase 2 study (SGN35-027 Part C)
Brentuximab Vedotin | PTCL | Abstract #3074
PET4 response as an independent predictor of outcomes in ECHELON-2 A+CHP vs CHOP in CD30+PTCL: Long-term follow-up
Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #608
Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced stage classical Hodgkin lymphoma: Updated efficacy and safety results from the single arm phase 2 study
Brentuximab Vedotin | Hodgkin Lymphoma | Abstract #4435
Brentuximab vedotin in frontline therapy of Hodgkin lymphoma in patients with significant comorbidities ineligible for standard chemotherapy (SGN35-015 Part E)